My Fragile Excitement

A number of readers have emailed me to ask my thoughts on the Neuren Phase II outcome in Fragile X. I initially wasn’t inclined to pass comment, mainly because I didn’t feel like getting a lot of flack from angry parents of Fragile X patients, criticising me for my lack of faith in Neuren (ASX…

PAA: Congratulations to Roger and the team…

Monumental day! Well done, another bit of doggy data for PharmAust … to follow all the other bits of doggy data we have received this year. Yaaaay! I think for all the world’s cancer patients, Executive Chairman Dr. Roger Aston’s comments bode particularly well, especially for women : Combining chemotherapy with PPL-1 in a target species with…

Novogen : Unacceptable Behaviour (Part II)

In this continuation of my prior rant about Novogen CEO Graham Kelly’s questionable interactions with shareholders on HotCopper, I want to specifically review each of the “questions” that appeared on HotCopper and perhaps share some perspectives that will help you to understand why I really despise this kind of informal chit-chat. I note that I have…

Neuren – A Can of Worms

Firstly, I would like to start this post by promoting another blog – specifically Trail to a Texas Trial. For anyone who is passionate about Rett Syndrome, it is powerful and emotional reading. I received a rather scathing retort from Melinda Lancaster, the owner of the site and the mother of a girl named Katelin who is…

Almost Antisensible

I don’t fully “get” Antisense Therapeutics (ASX : ANP). Some fairly challenging disease areas, a lot of irons (too many) in the fire and a slightly awkward ownership and partnership structure. I haven’t decided yet how I feel about their clinical candidates (and need to brush up on my endocrinology) but to be fair, the company seems…